Chai Discovery builds AI foundation models designed to predict and reprogram biochemical molecular interactions, with the goal of transforming drug discovery into an engineering discipline. The company's founders are researchers who co-invented protein language modeling and developed state-of-the-art protein folding algorithms. Chai Discovery is backed by OpenAI, Thrive Capital, and General Catalyst, and has a partnership with Eli Lilly.
The company's core platform - anchored by its Chai-1 and Chai-2 models - predicts and redesigns interactions between biochemical molecules at atomic precision. Key capabilities include drug-like antibody design against challenging targets and the generation of functional GPCR agonists with minimal screening. The platform has reported a success rate of over 85% for computationally designed molecules meeting drug-like properties, a figure that contrasts with the traditional approach of screening millions or billions of protein sequences over years at a cost of billions of dollars.
Chai Discovery's technical work spans several domains:
- Protein language modeling and folding algorithms
- Computational protein and antibody design
- GPCR agonist design
- Biopharma-focused machine learning
- Computational prediction of biochemical interactions
The company focuses on targets traditionally considered undruggable, positioning its platform as a tool capable of addressing therapeutic challenges that conventional methods cannot efficiently reach.
